The kidneys play a central role in PFAS pharmacokinetics — they filter PFAS from blood and are responsible for renal PFAS excretion. This ongoing exposure makes kidneys a key target of PFAS toxicity. Research has linked PFAS to kidney function impairment, uric acid elevation, and increased chronic kidney disease risk.
PFAS and Glomerular Filtration Rate
The glomerular filtration rate (GFR) is the primary measure of kidney function. Lower GFR indicates reduced kidney filtering capacity. Several epidemiological studies have found inverse associations between serum PFAS levels and estimated GFR (eGFR), suggesting that higher PFAS exposure is associated with reduced kidney function.
A large cross-sectional study using NHANES data found that adults in the highest quartile of PFAS exposure had meaningfully lower eGFR values compared to those in the lowest quartile. These associations were observed for multiple PFAS compounds and persisted after adjustment for diabetes, hypertension, and other kidney disease risk factors.
Uric Acid and Gout Risk
PFAS exposure has been consistently associated with elevated serum uric acid levels. Uric acid is normally excreted by the kidneys, but PFAS may compete with uric acid for renal transport proteins, reducing uric acid clearance. Elevated uric acid (hyperuricemia) is the primary risk factor for gout and may also contribute to cardiovascular and kidney disease progression.
Studies in both adults and children have found positive associations between PFAS blood levels and serum uric acid. Children with higher PFAS exposure showed elevated uric acid in several cohort studies, raising concern about early-onset gout risk and potential kidney effects beginning in childhood.
Chronic Kidney Disease and PFAS
Chronic kidney disease (CKD) affects approximately 15% of American adults and is a leading cause of dialysis and kidney transplantation. Research examining PFAS as a potential contributor to CKD development has found suggestive associations, particularly in populations with high occupational or environmental exposure.
The mechanisms likely include direct tubular toxicity, glomerular damage from sustained PFAS filtration burden, and indirect effects through PFAS-associated hypertension and metabolic dysfunction. As CKD progresses, kidney clearance of PFAS slows, potentially creating a vicious cycle of accumulation and further damage.
Reducing Kidney Exposure Through Filtration
For individuals with existing kidney disease or risk factors for CKD — including diabetes, hypertension, and family history — reducing PFAS intake through water filtration may slow disease progression. Reverse osmosis systems remove 90–99% of PFAS from drinking water, substantially reducing the daily renal PFAS burden.
Nephrologists managing patients with CKD increasingly recognize environmental toxicant exposure as a modifiable risk factor. Discussing PFAS exposure assessment and filtration strategies with a kidney specialist can help integrate water quality into comprehensive kidney disease management.